drugset / Trial / NCT00376181

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181

Phase 3 Terminated 96 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of pioglitazone-azilsartan, once daily (QD), in subjects with type 2 diabetes mellitus with poor glycemic control.

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 20 mg Oral
Subject Azilsartan Unknown 40 mg Oral
Comparator Pioglitazone Small molecule 45 mg Oral